Vaccine Partnership Panacea Biotec has a strong track record with WHO, GAVI, UNICEF, and national immunization programs, plus ongoing vaccine supply agreements. This presents a sales opportunity to expand collaborations with global health organizations and government procurement programs for additional vaccine portfolios and turnkey supply arrangements.

UNICEF & CMSS Recent awards and procurements from UNICEF for bOPV and a new contract with Central Medical Services Society indicate active government and international agency demand. Target expansions into larger tender opportunities, long-term supply contracts, and multi-country immunization campaigns.

Vaccine Capacity DFC funding and capacity expansion for hexavalent vaccines suggest available production capacity and capital-backed growth. This enables scale-focused conversations around multi-year manufacturing partnerships, co-development opportunities, and enhanced supply reliability for large purchasers.

Therapeutic Brands Established pharmaceutical brands across transplantation, diabetes, oncology, and gastrointestinal segments (Pangraf, Mycept, Glizid, Livoluk, PacliAll) offer cross-sell and bundle opportunities alongside vaccines, targeting hospitals, specialty clinics, and global distributors seeking diversified portfolios.

Global Footprint WHO prequalified, US FDA approved facilities and presence in 145+ countries position Panacea Biotec as a trusted supplier with regional expansion potential. Sales prospects include new market entry via distributors, local manufacturing partnerships, and contract manufacturing for vaccine and non-vaccine products.